Virax Holdings Limited (ASX: VHL) has entered into a license agreement with the French biopharmaceutical company, Transgene S.A. (EPA: TNG) which grants Transgene an exclusive access to Virax's Co-X-Gene™ technology patents for use in two of Transgene's immunotherapeutic products, TG4010 (MVA-MUC1-IL2) and TG4001 (MVA-HPV-IL2).
TG4010 (MVA-MUC1-IL2) and TG4001 (MVA-HPV-IL2) are both undergoing Phase IIb clinical trials for the treatment of non small cell lung cancer (TG 4010) and in preparation for Phase III trials against Human Papilloma Virus-associated pathologies, respectively.
Terms of agreement include:
- Virax will receive an upfront license fee and will share in fees and milestone payments received by Transgene in the event that it licenses out either of the products covered by the Co-X-Gene™ technology license and they achieve agreed development milestones.
- Virax could receive up to US$12 million under the agreement (US$9 million for TG4010 and US$3 million for TG4001).
- Virax will receive a royalty on net sales of the licensed products in North America.
Other financial terms of the agreement were not disclosed.
Find more details from the press release.
Comment Preview